Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects

Antimicrobial Agents and Chemotherapy

Volumn 42, Issue 8, 1998, Pages 2060-2065

  Stass, H ^a   Dalhoff, A ^a   Kubitza, D ^a   Schuhly U ^a  

^a BAYER AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

MOXIFLOXACIN; QUINOLONE DERIVATIVE; UNCLASSIFIED DRUG;

ACNE; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARTMENT MODEL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SALIVA LEVEL; DRUG TOLERABILITY; DRUG URINE LEVEL; EAR DISEASE; FLU LIKE SYNDROME; GASTROINTESTINAL SYMPTOM; HEADACHE; HERPES LABIALIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031903272     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.42.8.2060     Document Type: Article

References (17)

1. Borner, K., G. Höffken, H. Lode, P. Koeppe, C. Prinzing, P. Glätzel, R. Wiley, P. Olschewski, and B. Sievers. 1986. Pharmacokinetics of ciprofloxacin after oral and intravenous administration. Eur. J. Clin. Microbiol. 5:179-186.
2. Dalhoff, A., U. Petersen, and R. Endermann. 1996. In vitro activity of BAY 12-8039, a new 8-methoxyquinolone. Chemotherapy (Basel) 42:410-425.
3. Domdey-Bette, A. (Bayer AG). 1996. Private communication.
4. Gibaldi, M., and D. Perrier. 1982. Pharmacokinetics. Marcel Dekker, Inc. New York, N.Y.
5. Heinzel, G., R. Woloszczak, and P. Thomann. 1993. Topfit 2.0, pharmacokinetic and pharmacodynamic data analysis system for the PC. Gustav Fischer, Stuttgart, Germany.
6. Jacobs, E., A. Dalhoff, and H. Brunner. 1996. Efficacy of BAY 12-8039 in Mycoplasma pneumoniae infected guinea pigs, abstr. F17, p. 102. In Program and abstract of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
7. Kubitza, D., H. H. Stass, W. Wingender, and J. Kuhlmann. 1996. BAY 12-8039 (I), a new 8-methoxy-quinolone: safety (S), tolerability (T) and steady state pharmacokinetics (PK) in healthy male volunteers, abstr. F25, p. 104. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
8. Petersen, U., A. Dalhoff, R. Endermann. 1996. Synthesis and in vitro activity of BAY 12-8039, a new 8-methoxy-quinolone, abstr. F1, p. 100. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
9. Rouse, M. S., K. E. Piper, R. Patel, W. R. Wilson, and J. M. Steckelberg. 1996. In vitro and in vivo activity of BAY 12-8039 or trovafloxacin against penicillin-resistant Streptococcus pneumoniae experimental pneumonia in immunocompetent mice, abstr. B45, p. 29. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
10. Smith, K., A. Weber, R. Pandher, J. Williams-Warren, M. L. Cohen, and B. Ramsey. 1997. Utilization of salivary concentrations of ciprofloxacin in subjects with cystic fibrosis. Infection 25:106/38-108/40.
11. Stass, H. H., and A. Dalhoff. 1997. Determination of BAY 12-8039, a new 8-methoxy-quinolone, in human body fluids by HPLC with fluorescence detection using on column focusing. J. Chromatogr. 702:163-174.
12. Stass, H., D. Kubitza, V. Schüly, and W. Wingendes. 1997. Pharmacokinetics, safety, and tolerability of 800 mg BAY 12-8039 administered orally as a single dose. In Program and abstracts of the 8th European Congress of Microbiology and Infectious Diseases, Lausanne, Switzerland.
13. Vohr, H. W., G. Wasinska-Kempa, and H. J. Ahr. 1996. Studies on the phototoxic potential of BAY 12-8039, abstr. B45, p. 29. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
14. Waterbury, K., J. J. Wang, M. Barbiero, J. Federici, A. C. Ohlin, and E. D. Huguenel. 1996. Efficacy of BAY 12-8039, a potent new quinolone, in mouse models of typical and atypical respiratory infection, abstr. F18, p. 101. In Program and abstracts of the 36th Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
15. Wingender, W., K.-H. Graefe, W. Gau, D. Förster, D. Beermann, and P. Schacht. 1984. Pharamcokinetics of ciprofloxacin after oral and intravenous administration in healthy volunteers. Eur. J. Clin. Microbiol. 3:355-359.
16. Zeiler, H. J., U. Petersen, W. Gau, and H. J. Ploschke. 1987. Antibacterial activity of the metabolites of ciprofloxacin and its significance in the bioassay. Drug. Res. 37:131-134.
17. Zhai, S., X. Wei, B. Parker, K. Kunze, and R. E. Vestal. 1995. Do saliva concentrations predict plasma concentrations of enoxacin, ciprofloxacin and theophylline. Clin. Pharmacol. Ther. 57:191. (Abstract PII-110.)